Creative Planning Sells 503 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Creative Planning trimmed its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 4.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,158 shares of the medical device company’s stock after selling 503 shares during the quarter. Creative Planning’s holdings in Cooper Companies were worth $1,121,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Innealta Capital LLC bought a new stake in shares of Cooper Companies in the 2nd quarter valued at approximately $25,000. Covestor Ltd increased its position in shares of Cooper Companies by 305.9% in the 1st quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock valued at $28,000 after buying an additional 208 shares in the last quarter. Crewe Advisors LLC lifted its holdings in shares of Cooper Companies by 286.4% during the 2nd quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 252 shares in the last quarter. Tortoise Investment Management LLC boosted its holdings in shares of Cooper Companies by 75.4% in the second quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock valued at $34,000 after buying an additional 169 shares during the period. Finally, Clearstead Trust LLC acquired a new stake in shares of Cooper Companies in the 1st quarter valued at about $36,000. Institutional investors own 24.39% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Robert W. Baird boosted their price target on Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, August 29th. Stifel Nicolaus reaffirmed a “buy” rating and set a $115.00 price target (up previously from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th. Wells Fargo & Company boosted their target price on Cooper Companies from $110.00 to $115.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Finally, Morgan Stanley raised their price objective on Cooper Companies from $95.00 to $104.00 and gave the company an “equal weight” rating in a report on Tuesday, September 10th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus price target of $117.00.

Insider Activity

In other Cooper Companies news, CEO Albert G. White III sold 114,992 shares of Cooper Companies stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the transaction, the chief executive officer now owns 165,273 shares of the company’s stock, valued at $18,267,624.69. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Albert G. White III sold 114,992 shares of the stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the completion of the transaction, the chief executive officer now directly owns 165,273 shares of the company’s stock, valued at $18,267,624.69. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brian G. Andrews sold 24,788 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $105.90, for a total value of $2,625,049.20. Following the completion of the sale, the chief financial officer now owns 6,614 shares in the company, valued at $700,422.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 256,373 shares of company stock worth $27,637,427 over the last 90 days. 2.00% of the stock is currently owned by corporate insiders.

Cooper Companies Price Performance

Shares of COO opened at $104.68 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.99. The Cooper Companies, Inc. has a 52-week low of $77.01 and a 52-week high of $112.38. The business’s 50 day moving average price is $106.55 and its two-hundred day moving average price is $96.96. The firm has a market cap of $20.85 billion, a PE ratio of 58.16, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.91 by $0.05. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $997.30 million. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.84 earnings per share. On average, equities analysts anticipate that The Cooper Companies, Inc. will post 3.65 EPS for the current year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.